Results 101 to 110 of about 22,136 (209)

Escitalopram for psychiatric disorders [PDF]

, 2019
Evaluar la eficacia y seguridad, así como documentos relacionados a la decisión de cobertura de escitalopram en trastornos psiquiátricos comparado con fluoxetina y ...
Calderón Cahua, María
core  

Psychopharmacological Prescribing Patterns Among Italian Adolescents With Anorexia Nervosa: Exploring Real‐World Treatment Practices

European Eating Disorders Review, Volume 34, Issue 6, Page 1626-1636, November 2026.
ABSTRACT Objective To investigate real‐world psychopharmacological prescribing patterns among Italian adolescents with anorexia nervosa (AN) compared with psychiatric controls without eating disorders, and to examine whether AN diagnosis independently predicts medication use after accounting for psychiatric comorbidities.
Marika Orlandi, Arianna Vecchio, Giulia Andorno, Maria Pia Riccio, Cinzia Crispino, Martina Maria Mensi   +5 more
wiley   +1 more source

A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 11, November 2026.
ABSTRACT Introduction Pharmacodynamic drug–drug interactions (DDI) in patients receiving oral anticoagulants (OAC) may increase the risk of gastrointestinal bleeding (GIB). The purpose of this study was to develop and validate a GIB model for patients receiving OACs.
Ainhoa Gomez‐Lumbreras, Abdelrahman G. Tawfik, Thomas Reese, Daniel M. Witt, Guilherme Del Fiol, Daniel C. Malone   +5 more
wiley   +1 more source

Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation

, 2017
International audienceSelective serotonin reuptake inhibitors (SSRI) are common antidepressants which cytotoxicity has been assessed in cancers notably colorectal carcinomas and glioma cell lines.
Youssef Aissouni, Chalus, Maryse, Nathalie Delétage, Coll, Guillaume, Stéphane Gobron, Laurent Sakka, Guillaume Coll, Delétage, Nathalie, Aissouni, Youssef, Sakka, Laurent, Sylvain-Vidal, Valérie, Gobron, Stéphane, Valérie Sylvain-Vidal, Maryse Chalus   +13 more
core   +1 more source

Patients With Atypical Symptoms of Depression Respond Better to Lithium Augmentation Than Patients Without Atypical Symptoms

Acta Psychiatrica Scandinavica, Volume 154, Issue 5, Page 376-383, November 2026.
ABSTRACT Introduction Understanding the differences in treatment response between subtypes of major depressive disorder (MDD) may help to prevent lengthy trial‐and‐error processes by identifying effective treatment options. The aim of the study was to investigate the impact of atypical features of MDD (MDD‐A) on the response to lithium augmentation (LA)
Hannah Buchbauer, Mazda Adli, Peter Schlattmann, Maximilian Berger, Tom Bschor, Thomas Stamm, Joachim Behr, Roland Ricken, Pichit Buspavanich   +8 more
wiley   +1 more source

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo

Escitalopram is the most selective of the serotonin reuptake inhibitor (SSRI) antidepressants. We conducted a meta-analysis of placebo-controlled studies where escitalopram was used to treat patients with social anxiety disorder (SAD).
Baldwin, D., Asakura, S., Reines, E., Hayano, T., Koyama, T., Larsen, K., Hagino, A.   +6 more
core   +2 more sources

Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study

, 2006
BACKGROUND: It is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder. AIMS: To assess the efficacy of different doses of escitalopram in generalised anxiety disorder.
Baldwin, David S., Huusom, Anna Karina Trap, Mæhlum, Eli   +2 more
core   +1 more source

Comparative Evaluation of Antidepressant and Anxiolytic Effects of Escitalopram, Crocin, and their Combination in Rats

Advanced Biomedical Research
Background: Chronic stress can lead to anxiety and depression. Escitalopram is a selective serotonin reuptake inhibitor (SSRI), and crocin is a natural compound derived from saffron.
Mehran Joodaki, Maryam Radahmadi, Hojjatallah Alaei   +2 more
doaj   +1 more source

Baseline characteristics for the escitalopram cohort (pre and post weighting).

, 2016
Baseline characteristics for the escitalopram cohort (pre and post weighting).
Lorne J. Gula (2938113), Akshya Vasudev (2938104), Matthew J. Oliver (278084), Danielle M. Nash (2938098), Stephanie N. Dixon (2938110), Eric McArthur (651305), Matthew A. Weir (2557285), Elena Qirjazi (2938101), Amit X. Garg (445776), Racquel Jandoc (2938095), Ron Wald (2938107)   +10 more
core   +1 more source

Protective Effects of Long-Term Escitalopram Administration on Memory and Hippocampal BDNF and BCL-2 Gene Expressions in Rats Exposed to Predictable and Unpredictable Chronic Mild Stress

Brain Sciences
Stress and escitalopram (an anti-stress medication) can affect brain functions and related gene expression. This study investigated the protective effects of long-term escitalopram administration on memory, as well as on hippocampal BDNF and BCL-2 gene ...
Vajihe Saedi Marghmaleki, Maryam Radahmadi, Hojjatallah Alaei, Hossein Khanahmad   +3 more
doaj   +1 more source